Maharashtra FDA puts Vimal surrogate-ad campaign under scrutiny

Maharashtra FDA has issued show-cause notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff over Vimal Elaichi ads, alleging they promote prohibited Vimal Pan Masala by proxy. The celebrities have 15 days to respond; unsatisfactory replies could invite fines of up to Rs 10 lakh.

— Source published Tue, 18 Aug, 2026, 21:38 IST · First seen Tue, 18 Aug, 2026, 21:56 IST · Source NDTV Profit

What happened

Maharashtra FDA issued show-cause notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff over Vimal Elaichi advertisements, alleging surrogate promotion of

Key facts

  • Rs 10 lakh
  • 15 days
  • nine-page notice

Why this matters

Corporate-development teams should diligence surrogate-advertising exposure, endorsement contracts and regulatory contingencies when assessing FMCG brands built on restricted-category extensions.

What to watch

  • Whether the celebrities respond within the 15-day window and whether Maharashtra FDA imposes fines or closes the notices after explanations.
  • Any finding that specific Vimal Elaichi packaging, trademarks, taglines or visuals constitute indirect promotion of Vimal Pan Masala.
  • Similar notices from other state FDAs, the Union health ministry, CCPA, ASCI or broadcast regulators.
  • Broadcaster, cinema-chain, outdoor-media and social-platform decisions to remove or restrict the ads.
  • Endorser withdrawals, contract non-renewals or public statements from Shah Rukh Khan, Ajay Devgn or Tiger Shroff.
  • Sales and distribution shifts between Vimal Elaichi, Vimal Pan Masala and rival mouth-freshener brands following campaign changes.
  • Vimal is likely to file individual celebrity responses emphasizing that elaichi is a lawful standalone product and that ads do not explicitly promote pan masala.
  • The company may pause, edit or rotate the highest-visibility commercials, especially creatives using shared Vimal master-brand cues, packaging colors or pan-masala associations.
  • Celebrity managers and talent agencies may seek public clarification, contractual indemnities and pre-clearance rights for future regulated-category endorsements.
  • Media owners, ad agencies and digital platforms may require stronger legal opinions and ASCI-style substantiation before accepting brand-extension campaigns.
  • Competing FMCG advertisers may use the regulatory uncertainty to bid for celebrity inventory and premium media slots previously occupied by Vimal-linked campaigns.